Agilent Showcases Cancer Research Solutions at AACR 2026
Agilent Showcases Cancer Research Solutions at AACR 2026
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags
Key Terms
companion diagnosticsmedical
A companion diagnostic is a medical test used alongside a specific drug or therapy to identify which patients are likely to benefit from it or may face safety risks. Think of it as a tailored matchmaker that tells doctors whether a particular treatment is a good fit for an individual. For investors, these tests matter because they can shape a drug’s approved use, speed and cost of development, patient uptake, reimbursement, and the commercial value of both the therapy and the diagnostic.
cell imagingmedical
Cell imaging is the process of taking detailed pictures or videos of living or fixed cells using specialized microscopes and cameras to watch their structure, behavior and responses to treatments. For investors, it's important because those images provide direct evidence about whether a drug, diagnostic or lab technology works as intended, helping estimate how quickly a product can advance, how risky development is, and whether a company’s science is credible.
multimode microplate readerstechnical
A multimode microplate reader is a laboratory instrument that measures chemical or biological reactions in flat plates with many tiny wells, using several detection methods (like color change, glow, or fluorescence) all in one device. Think of it as a Swiss Army knife for lab measurements; it speeds testing, reduces the need for multiple instruments, and matters to investors because broad functionality drives sales across drug discovery, diagnostics and quality-control markets and supports recurring consumable and service revenue.
ai‑enabled softwaretechnical
Software that uses artificial intelligence techniques to perform tasks that normally require human judgment—such as spotting patterns in large data sets, making predictions, automating decisions, or understanding language and images. For investors, it matters because ai‑enabled software can boost productivity, create new revenue streams and competitive advantages like a smart assistant that speeds and scales work, but it also brings risks around accuracy, data quality, regulation and ongoing maintenance costs.
long‑read sequencingmedical
Long-read sequencing is a laboratory method that reads very long stretches of DNA or RNA in one pass, like reading whole chapters of a book rather than short snippets. For investors it matters because the longer, more complete reads can reveal complex genetic changes and improve diagnostic accuracy, drug target discovery, and costly follow-up work, affecting demand for sequencing instruments, services, and downstream clinical or agricultural applications.
methylation profilingmedical
Methylation profiling is a laboratory method that maps small chemical markers placed on DNA that act like sticky notes controlling whether genes are read or ignored, much like flags on pages of an instruction manual. For investors, these profiles can reveal disease signatures, help identify patients likely to respond to a therapy, and create diagnostic or drug-development opportunities that affect clinical success, regulatory approval and commercial value.
structural variant analysismedical
Structural variant analysis is the process of finding and interpreting large-scale changes in an organism's DNA—such as missing sections, extra copies, flipped pieces, or pieces that moved to a new location. Think of it like checking a book for torn pages, duplicated chapters, or paragraphs stuck in the wrong place; these changes can dramatically alter how genes work. For investors, this analysis matters because it underpins genetic diagnostics, drug target identification, and the commercial value of therapies and tests that rely on accurate detection of these big DNA changes.
target enrichmenttechnical
Target enrichment is a laboratory method that pulls out and concentrates specific genes or other molecular regions of interest from a complex biological sample before testing, like using a magnifying glass to focus on a single page instead of reading an entire book. For investors, it matters because it reduces testing cost and time, increases accuracy for diagnostics and drug research, and can make targeted therapies and companion tests more commercially viable.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SANTA CLARA, Calif.--(BUSINESS WIRE)--
Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum.
Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode microplate readers. Cytation 9 is designed to support advanced live‑cell and endpoint assays by combining automated microscopy with conventional microplate reading in a single system, supporting a range of cell‑based research applications.
In addition, Agilent will provide an early preview of the upcoming AI‑enabled software enhancement for the xCELLigence RTCA eSight, designed to bring the same straightforward, objective data analysis long valued in impedance measurements to label‑free live‑cell imaging, while supporting more consistent, reproducible results.
AACR attendees are invited to join Agilent at the Exhibitor Spotlight Theater for a session titled “Direct Targeted Methylation Sequencing (dTMS) with SureSelect: Targeted Long‑Read Sequencing for Native Variant and Methylation Profiling in Oncology.” The session will be presented by Andrew Jenkins, biotechnology research associate at Wasatch Biolabs, and will examine the use of targeted long‑read sequencing approaches in oncology research.
Agilent will also highlight its collaboration with Oxford Nanopore Technologies, demonstrating the compatibility of Agilent SureSelect target enrichment chemistry with ONT’s long-read sequencing platforms. By integrating SureSelect libraries into ONT sequencing workflows, researchers can pair hybrid-capture target enrichment with real-time, long-read sequencing to support applications such as target genomics, structural variant analysis, and methylation profiling.
Immediately preceding AACR 2026, Agilent’s xCELLigence User Group Meeting will bring together the real-time cell analysis community to share best practices, applications, and real-world insights from functional cell-based research.
Agilent is continuing its collaboration with the AACR Foundation following a virtual 5K fundraiser held in October 2025 that raised $15,000 and funded 14 Scholars-in-Training awards. Agilent representatives will meet scholars supported through this initiative at the AACR Scholar‑in‑Training Award Reception and will promote the 5k fundraiser at the Agilent booth as part of its ongoing commitment to supporting early-career cancer researchers.
“At Agilent, our mission is to support advances in cancer research by providing integrated technologies and collaborative solutions,” said Rita Shaknovich, chief medical officer at Agilent Technologies. “By delivering trusted answers, we aim to help researchers and clinicians make more informed decisions across the cancer research and care continuum.”
Agilent will exhibit at booth No. 4527 and host additional scientific and networking events throughout the meeting.
About Agilent Technologies
Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
